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Abstract: Multiple tissues and systems in the organism undergo modifications during aging due to
an accumulation of damaged proteins, lipids, and genetic material. To counteract this process, the cells
are equipped with specific mechanisms, such as autophagy and senescence. Particularly, the immune
system undergoes a process called immunosenescence, giving rise to a chronic inflammatory status
of the organism, with a decreased ability to counteract antigens. The obvious result of this process is
a reduced defence capacity. Currently, there is evidence that some pathogens are able to accelerate
the immunosenescence process for their own benefit. Although to date numerous reports show
the autophagy–senescence relationship, or the connection between pathogens with autophagy or
senescence, the link between the three actors remains unexplored. In this review, we have summarized
current knowledge about important issues related to aging, senescence, and autophagy.
Keywords: aging; senescence; autophagy; immune system; immunosenescence; pathogens;
chronic infections
1. Introduction
The functionality of organs such as the brain or the immune system differs when comparing
young and old individuals. Those differences are due to changes at both, molecular level (loss of
chromatin, accumulation of mutations in the DNA, protein oxidation and misfolding), and at the
cellular level (increased oxidative stress, changes in the membrane fluidity, aggregation of proteins,
and accumulation of damaged organelles). All together, these changes generate a gradual change in
the functionality of the entire organism, a process called aging.
In multicellular organisms, the aging process starts at the end of development, when tissues
and organs reach the maximal and final stage of differentiation. At this point, tissues are classified
into those formed by non-proliferative cells (they have a post-mitotic arrest) and those composed by
proliferative cells bearing the ability of regeneration (mitotic cells). Along the lifetime, both types of
tissues accumulate damage, though with different consequences. The effect of aging on mitotic cells are
evidenced by an increase in the incidence of cancer after the age of 50 due to accumulation of mutations
by DNA damage, while on non-mitotic cells, the main effects are the appearance of neurodegenerative
disorders or cancer with increased rates after the age of 70 mainly due to the presence of damaged
proteins and organelles [1].
Cells are equipped with a plethora of strategies to counteract the effects of aging by
degradation and recycling of damaged organelles and molecules. Autophagy, together with the
ubiquitin/proteasome system are the major degradative pathways within the cells [2]. Moreover,
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autophagy has the capacity to eliminate proteins and old or damaged organelles, a role named
quality control function [3] by which the pathway prevents the accumulation of agents that could
potentially damage DNA. Besides, there is evidence that autophagic proteins are directly involved in
the maintenance of DNA stability [4,5]. This degradative process is mediated through three different
mechanisms i.e., chaperone-mediated autophagy (CMA), microautophagy, and macroautophagy [2].
CMA is a selective process based on the recognition of specific KFERG-like motifs. This multistep
process requires (1) substrate recognition and target to lysosomes; (2) binding and unfolding;
(3) translocation and (4) degradation in the lumen of lysosomes [3,6,7]. The two key molecules
involved in CMA are Hsp70 (Heat shock protein 70) and LAMP2A (Lysosomal associated membrane
protein 2 A). The recognition and binding of the substrate occurs in the cytoplasm by Hsp70 and
subsequently this complex binds to Lamp2A in the lysosome membrane. This complex together with
other proteins participate in the transport of the previously mentioned unfolded substrate [8] to the
lysosomal lumen where it is degraded [3,6,7].
Microautophagy refers to the process involving membrane modification in the lysosomes
(protrusions or invaginations) where different substrates are trapped and finally degraded [9].
Microautophagy breaks down proteins and pieces of organelles (mitochondria, peroxisome, and lipid
droplet) [10]. This mechanism has been mainly described in yeast, and in mammals, a similar
mechanism has been observed, but associated with late endosomes/multivesicular bodies (LE/MVB)
and termed endosomal microautophagy (eMI) [11]. eMI depends on the ESCRT machinery and
surprisingly in some cases of Hsp70 (and KFERG like motif) [11]. Interestingly, the pool of substrates
bound to Hsp70 that is degraded by this pathway does not depend on the unfolded state [8,11] and
in mammals different from yeast, the KFERG-like motif is necessary but not sufficient to target the
substrates into endosomes [12]. An extra unknown signal is necessary to the targeting of Hsp70 bound
substrates to eMI.
Macroutophagy (hereafter called autophagy) begins with the generation of a structure called
isolation membrane, which is then closed generating a double membrane vesicle. In these vesicles
called autophagosomes, the material to be degraded is sequestered and placed in contact with
degradative enzymes after the fusion of autophagosomes with late endosomes and lysosomes [13].
During the process, several protein complexes participate and regulate different steps of the pathway.
The biogenesis of autophagosomes initiates with the phosphorylation and dephosphorylation of the
ULK1 complex (ULK1/2, FIP200, Atg13, and Atg101), followed by the activation of the Vps34 lipid
kinase complex (VPS34, Atg14L, BECN1, VPS15) which generates PI(3)P. This lipid recruits the proteins
ZFYVE and WIPI, locating the Atg5-12-16L complex, and inducing LC3 protein processing by adding
a hydrophobic tail that allows it to anchor to the lipidic membranes. The activity of these proteins’
complex generates a deformation in the membranes that ends with the formation of an autophagosome.
Finally, the autophagosomes fuse with other endosomes and lysosomes to acquire the degradative
characteristics [14].
Initially, autophagy was considered a bulk degradation pathway where the entrapped materials
were degraded non-specifically. Currently, we know that several recognition molecules or adapters
mediate incorporation of material into autophagosomes. Among them, NCK, p62/sequestosome1
(SQSTM1), or NDP52 recognize molecules such as ubiquitin bound to proteins and direct its
degradation (reviewed in Ref. [15]). Aged or damaged organelles are also specifically degraded
by autophagy. In the context of aging, it is particularly important to mention the participation of
autophagy in the maintenance of mitochondrial homeostasis. In the cell, there exist several pathways
for targeting mitochondria to autophagic degradation, a process called mitophagy. In the normal
metabolism of mitochondria, low levels of ROS are produced. These low levels have a physiological
role, whereas high levels of ROS can oxidize nucleic acids, lipids, and proteins leading to cellular
dysfunction and programmed cell death [16]. Thus, it is important to clear damaged mitochondria
because they can trigger programmed cell death [17], inflammation, and aging [18], and may also
participate in many pathophysiological processes [19]. Currently, evidence indicates that Pink1
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and Parkin [20,21] or FKBP38, in a Parkin-independent fashion [22], could recognize dysfunctional
mitochondria, thus promoting their degradation in a process called mitophagy. In the regulation
of mitophagy, the most studied signal is the system Pink1/Parkin. This mechanism involves the
ubiquitination of specific mitochondrial domains by Parkin as a consequence of Pink1 activation when
mitochondria is depolarized. After ubiquitination, the receptors p62/SQSTM1, NBR1, and optineurin
recruit LC3 via their LC3-interacting region (LIR) [23–26]. In the case of the mitophagy that depends
on FKBP38, the recruitment of LC3 occurs by direct binding to a LIR domain present in the FKBP38
protein, [22]. Similar to the FKBP38-dependent mechanism, a group of transmembrane receptors
anchored to the mitochondrial membrane could recruit LC3 using a special LIR domain regulated by
phosphorylation. This group includes Bnip3 and Bnip3L/Nix, FUNC1, and Bcl2L13/Bcl-Rambo [27].
In summary, the different forms of autophagy, including very specific forms such as mitophagy,
play a key role in controlling cellular damage, thus preventing further deterioration processes.
Besides the homeostatic functions, the autophagic pathway acts as a defence mechanism against
intracellular pathogens. Xenophagy, a specialized type of autophagy, is a pathway able to recognize
pathogens in the cytoplasm or within damaged phagosomes employing adaptor molecules [28–30].
Some pathogens have evolved strategies to evade degradation after phagocytosis. This strategy
includes blockage of phagosome maturation, generation of small piercings into phagosomal
membranes or breaking down of the phagosome, and escape to the cytosol [31]. The autophagic
pathway can counteract some of these pathogen strategies. After their escape to the cytoplasm,
pathogens are ubiquitinated and receptors like p62 or NDP52 direct them to the autophagic pathway
by using LIR and ubiquitin (UB) binding domains [30,32–34]. However, escape to the does not
need to be recognized by autophagy, since bacteria inside damaged phagosomes/phagolysosomes
can also be ubiquitinated. Additionally, vesicles of different maturation stages in the phagocytic
pathway present carbohydrates in their lumen that are not normally exposed to the cytoplasm.
When phagosomes/phagolysosomes are damaged by the microorganisms, those carbohydrates are
exposed, becoming recognisable to specific molecules which collaborate in the autophagic response.
Particularly, galectins are recruited to damaged vesicles [32,35] and it has been reported that galectin
8, through binding with NDP52, collaborates in the recruitment of the autophagic machinery to
Salmonella-containing vacuoles [32].
Then, global autophagy activation (macro-, micro-, and CM-autophagy, mitophagy, and xenophagy)
is the first potent barrier against situations potentially causing harsh cellular damage (Figure 1) [36].
In fact, available data show that a decrease in autophagy activity is associated with the aging process,
where accumulation of damaged cells leads to the malfunctioning of tissues in aged organisms [37].
In an interesting work, Garcia-Prat and collaborators showed that basal autophagy is essential to maintain
the stem-cell quiescent state in mice. Failure of autophagy in physiologically aged satellite cells, or genetic
impairment of autophagy in young cells, causes entry into senescence by loss of proteostasis, increased
mitochondrial dysfunction, and oxidative stress, resulting in a decline in the function and number of
satellite cells. Re-establishment of autophagy reverses senescence and restores regenerative functions in
geriatric satellite cells, indicating that autophagy is necessary to normal regenerative activity of muscle
tissue by maintaining satellite stem cell in a quiescent state.
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include arrest of proliferation, resistance to apoptotic signals, and alteration in gene expression [43]. 
Phenotypically, senescent cells present flat morphology and increased cell size in vitro. Changes in 
the chromatin and nuclear morphology have been also observed [44,45]. A key feature is an 
accumulation of senescence-associated (SA) β-galactosidase, a lysosomal enzyme that has been 
broadly used as a senescence marker since it becomes easily detected by a conventional staining 
technique [46,47]. In addition, modifications in gene expression related to down-regulation of genes 
that promote cell cycle and up-regulation of oncogenes like p16INK4a and p21Waf-Cip1 [43,48] have 
been detected. Likewise, modifications have been described in an extensive list of genes codifying 
cytokines. Another characteristic of senescent cells is the secretion of growth-regulating, 
inflammatory, and tissue remodelling factors [49,50], a process referred to as the senescence-
associated secretory phenotype (SASP) [49,51,52]. SASP components actively participate in the 
senescence process and are used as markers of senescence [53]. For example, interleukin-6 (IL-6) and 
IL-8 act in an autocrine feedback loop to reinforce the senescence growth arrest [51,53]. In addition, 
secreted factors from senescent cells may act in a paracrine manner to trigger senescence [54,55]. IL-
6, IL-8, and other secreted factors attract immune cells that, together with the increased expression of 
immune cell-interacting molecules on senescent cells, can lead to immune surveillance and 
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Figure 1. Different stages of cell damage. Autophagy is one of the mechanisms acting as the first
barrier against cell damage to avoid the accumulation of non-functional organelles or proteins in the
cells. When this mechanism is overburdened, apoptosis or senescence is activated. These mechanisms
stop the damaged cells’ dissemination and prevent the apparition of age-related diseases, such as
neurodege erative disorders o cancer. An accumulation of damaged organelles and proteins and
changes in the genetic material are observed in these diseases.
When the autophagic barrier is overcome, cells have additional mechanisms involved in cellular
damage rescue. Proliferative tissues rely on two main strategies to avoid the dissemination of damaged
cells, i.e., apoptosis (programmed cell death) or senescence (proliferation arrest) (Figure 1). Apoptosis
and senescence appear to be mutually exclusive events and are cell type-dependent. Lymphocytes tend
to activate apoptosis, while damage fibroblasts and epithelial cells mainly undergo sen scence [1].
For further reading about apoptosis, we suggest reviews [38–40]. This review is mainly focuss d in the
link between autophagy and senescence in the context of infections.
The term “senescence” was first used by Hayflick and Moorhead in order to name the process
where cells stop dividing after a number of culture passages [41]. Current knowledge indicates that this
phenomenon is a consequence of telomere shortening and is called replicative senescence. Senescence,
however, is more complex process activated by a multiplicity of stress stimulus con ected to cellular
damage such as DNA damage, hypoxia, and accumulation of reactive oxygen species (ROS) [42].
All these stimuli seem to converge onto two major signalling pathways, involving two tumour
suppressor proteins, the retinoblastoma protein, pRb, and the p53 pathways [43].
Once activated, senescent cells undergo morphological and functional modifications,
which include arrest of proliferation, resistance to apoptotic signals, and alteration in gene
expression [43]. Phenotypically, senescent cells present flat morphology and increased cell size in vitro.
Changes in the chromatin and nuclear morphology have been also observed [44,45]. A key feature
is an accumulation of senescence-associated (SA) β-galactosidase, a lysosomal enzyme that has been
broadly used as a senescence marker since it becomes easily detected by a conventional staining
technique [46,47]. In addition, modifications in gene expression related to down-regulation of genes
that promote cell cycle and up-regulation of oncogenes like p16INK4a and p21Waf-Cip1 [43,48] have
been detected. Likewise, modifications have been described in an extensive list of genes codifying
cytokines. Another characteristic of senescent cells is the secretion of growth-regulating, inflammatory,
and tissue remodelling factors [49,50], a process referred to as the senescence-associated secretory
phenotype (SASP) [49,51,52]. SASP components actively participate in the senescence process and
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are used as markers of senescence [53]. For example, interleukin-6 (IL-6) and IL-8 act in an autocrine
feedback loop to reinforce the senescence growth arrest [51,53]. In addition, secreted factors from
senescent cells may act in a paracrine manner to trigger senescence [54,55]. IL-6, IL-8, and other secreted
factors attract immune cells that, together with the increased expression of immune cell-interacting
molecules on senescent cells, can lead to immune surveillance and subsequent elimination of senescent
cells. In the kidney, some of these factors promote tissue repair by recruiting immune cells that remove
damaged components, increase SASP and maintain homeostasis [56,57].
Senescence avoids cellular damage spreading by arresting the duplication of cells bearing
changes in their genetic information, thus limiting short-term tissue damage [58–62], and preventing
tumorigenesis [58,63–65]. Furthermore, it has been demonstrated that senescent cells are easily
eliminated by the immune system [66]. Dendritic cells, neutrophils, and macrophages were found
in the micro-environment of senescent cells [61,67,68]. In a model of mouse hepatic fibrosis, hepatic
stellated cells (HCS) undergo senescence and are specifically recognized and eliminated by NK
cells [61]. In a similar model, macrophages were able to eliminate HCSs expressing p53 [67].
2. Autophagy and Senescence
Based on the consideration that autophagy acts as the first barrier against situations of cellular
stress, the traditional point of view states that autophagy prevents senescence (Figure 1) [69,70].
However, when the damage is too extensive to be solved by autophagy, senescence is activated.
García-Prat and collaborators showed in 2016 that basal autophagy prevents senescence in muscle
stem cells, maintaining the “stemness” and their muscle regenerative nature [37]. In this work,
the authors showed that loss of autophagy capacity increases the dysfunction of mitochondria and,
as a consequence of an increase in oxidative stress, the senescence program becomes activated.
The regenerative capacity of muscle stem cells is restored when autophagy is re-established. Moreover,
it has been observed that the high enough accumulation of ROS leads to autophagy inhibition and
senescence activation [71,72]. This situation could be reversed by either mTOR inhibition or AMPK
activation (two key autophagy regulators), restoring the autophagic activity and, as a consequence,
preventing senescence [71–73]. Those works are mainly focused on macroautophagy and its role in
senescence activation, but CMA has also been related to this process. Senescent fibroblasts and tissues
from old organisms show a decrease in transcriptional up-regulation of Hsp70 in response to different
stressors [74] and changes have been described in the lipid composition of lysosomal membranes due
to aging, as well as accelerated Lamp2A degradation with concomitant protein level diminution [75].
There are some studies at the molecular level about the role of autophagy in senescence regulation.
It has been observed that autophagy inhibits senescence by modifying the levels of transcription
factor GATA4. This factor initiates the NFKB/NF-kB (nuclear factor kappa-light-chain-enhancer
of activated B-cells) transcriptional circuit, involved in SASP generation [76,77]. The autophagic
degradation of GATA4 is mediated by the adapter protein p62/SQSTM [77]. After senescence is
activated, the interaction between these two proteins decreases and GATA4 accumulates by escaping
from degradation.
Nevertheless, a positive role of autophagy in senescence has been reported. In 2009, Young
and collaborators showed in a model of oncogene-induced senescence that inhibition of autophagy
delayed senescence induced by the oncogene HRASG12V [78]. In the same work, the authors showed
that the autophagic pathway is induced in the context of senescence with an up-regulation of the
expression levels of several autophagy-related genes such as WIPI-1 and 4, p62, LC3B, Atg7, BNIP3L
due to senescence activation. Some years later, Narita and collaborators described the TOR-autophagy
spatial coupling compartment (TASCC), a specialized type of autophagy that is able to locally activate
mTOR by providing amino acids [79]. This compartment comprises a region of the cell where there is
an accumulation of autolysosome-like structures positive for β-galactosidase. Interestingly, mTOR
is associated with these structures and such association favours mTOR activation probably due to
local amino acids released by the autolysosomes. This activation, in turn, promotes the production
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of interleukins (IL) 6 and 8, two SASP factors. After this publication, several reports showed that
autophagy promotes senescence activation in different models such as fibroblasts in breast cancer
by overexpression of CDK (cyclin depending kinases) inhibitors [80] or in radioresistant cancer cell
lines by activation of mTOR. Finally, a recent study provided data showing a molecular mechanism
of senescence regulation by autophagy. Horikawa and collaborators demonstrated that the p53
inhibitor d133p53 (a p53 isoform) is degraded by autophagy after ubiquitination, which in turn leads
to senescence activation [81].
Taken together, the existing data show that autophagy could act dually (Figure 2). Firstly,
the pathway shows a negative modulation over senescence preventing damage accumulation in
the cell. On the other side, when the damage overloads the autophagic capacity, senescence is activated
and the autophagic pathway contributes to this activation.
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Figure 2. Autophagy has a dual role in senescence activation. There are several factors that
stimulate senescence activation. These includes ROS accumulation, hypoxia DNA damage, or telomere
shortening. Once activated, senescent cells undergo morphological and functional modifications,
which include arrest of proliferation, the resistance to apoptotic signals, size increasing, alteration in
gene expression, and activation f SASP. The autophagic pathway could prevent senescence due to its
capacity to eliminate p t tially dangerous elements generated in aging, such as damag d organelles
and proteins; and by collaborating in genome stability. Nevertheless, when senescence is activated,
autophagy plays a positive role by autophagic degradation of p53 inhibitors or by increasing the levels
of senescent cytokines between others.
3. The Aging of the Immune System
An important consequence of the age-dependent decrease of critical cell functions is the reduced
response against pathogen infections. Elderly peopl di lay a gre er propens ty to certain infectious
diseases and an i creased difficulty to resolve (combat) others, such as seaso al influenza [82] or
pneumonia [83]. Related to the immune response, a status of chronic elevated basal inflammation
called “inflammaging” characterized by a lower capacity to mount an effective immune response
against an infective agent have been described during aging [84]. As part of this process, a gradual
deterioration of the immu e response, known as i munose escence, occurs. Moreover, not only T-
and B-cells but also neutrophils, macrophages, and dendritic cells are affected (T ble 1), leading to
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the failure of an appropriate innate and adaptive immune response against microorganisms and an
attenuated immunological memory to new immunogens [85–88].
Table 1. Main effect of senescence over immune system.
Type of Immunity Cell Type Senescent Phenotype
Innate immunity
Neutrophils Phagocytic activitySuperoxide generation
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Table 1. Main effect of senescence over immune system. 
Type of 
Immunity 
Cell Type Sen sc nt Phenotype 
Innate 
immunity 
Neutrophils Phagocytic activity 
Superoxide generation  
Macrophages 
Phagocytic capabilities 
Super xide production 
MHC Levels 
 
Dendritic cells Migration capabilities  Alterations in phagocytic activity of apoptotic cells 
Adaptive 
immunity 
T
CD4(+) and CD8(+) CD28(+) 
Proportion CD8(+) CD28(+) 
Blood naïve CD8(+) 
Proliferative activity  
B-cells 
IgD(−) CD27(−)  
Basal levels of IL-10 and TNF-α  
In add tion to the phenotype variations of the CD4(+) a d CD8(+) T subpopulation, functional
chang s of T-c lls expl in most of the ag -related pathologies. Lymphocytes of lderly orga isms ar
already in a  activated state, unable to be up-regulated by external stimulation [96]. T e most affected
T-cell functions are clonal expansion and cytokine producti n, particularly IL-2 [97]. Additionally, a
reduced proliferative activity of these cells by senescence activation is observed. T-cells engage the
p38MAPK inhibitory signalling pathway in an pparently novel non-c no ical mechanism [98]. So,
by using small-molecule inhibitors [99] or specific inhibitory shRNA [100], it was ob erv d that
p38MAPK inhibition r consti uted proliferation and t lomerase activity in T-cells after act vation.
Senesc nt T-cells also show high levels of intr c llular granules containing the cy otoxic proteins
perforin and g anzyme B [101], a d secrete high levels of inflammatory cytokines such as interferon
(IFN)-γ and TNF-α after short-term activation [102]. Besides the age-related thymus regression, the 
lifetime’s accumulated exposure to infectious agents, autoantigens, and cancer antigens may also 
induce T-cells replicative senescence and clonal exhaustion, a concept well-established in the case of 
chronic infections. 
Alterations in phagocytic activity of apoptotic cells
Adaptive immunity
T-cells
CD4(+) and CD8(+) CD28(+)
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In addition to the phenotype variations of the CD4(+) and CD8(+) T subpopulation, functional 
changes of T-cells explain most of the age-related pathologies. Lymphocytes of elderly organisms are 
already in an activated state, unable to be up-regulated by external stimulation [96]. The most affected 
T-cell functions are clonal expansion and cytokine production, particularly IL-2 [97]. Additionally, a 
reduced proliferative activity of these cells by senescence activation is observed. T-cells engage the 
p38MAPK inhibitory signalling pathway in an apparently novel non-canonical mechanism [98]. So, 
by using small-molecule inhibitors [99] or specific inhibitory shRNA [100], it was observed that 
p38MAPK inhibition reconstituted proliferation and telomerase activity in T-cells after activation. 
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induce T-cells replicative senescence and clonal exhaustion, a concept well-established in the case of 
chronic infections. 
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In addition to the phenotype variations of the CD4(+) and CD8(+) T subpopulation, functional 
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already in an activated state, unable to be up-regulated by external stimulation [96]. The most affected 
T-cell functions are clonal expansion and cytokine production, particularly IL-2 [97]. Additionally, a 
reduced proliferative activity of these cells by senescence activation is observed. T-cells engage the 
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In add tion to the phenotyp  va iations of the CD4(+) and CD8(+) T subpopulation, functional
changes of -ce ls explain most of the age-related patholo ies. Lymphocytes of elderly organisms are
already in an activated state, unable to be up-regu ated by external stimulati n [96]. The most affected
T-cell functions are clonal expansion and cytokine production, particularly IL-2 [97]. Additionally, a
reduced proliferativ  activity of these cells by senescence activation is observed. T-cells eng ge the
p38MAPK inhibitory signalling pathway in an app rently novel non-canonical mechanism [98]. S ,
by us ng small-molecule inhibitors [99] or specific inhibitory shRNA [100], it was observed that 
p38MAPK inhibition reconstituted proliferation and telomerase activity in T-cells after activation. 
Senescent T-cells also show high levels of intracellular granules containing the cytotoxic proteins 
perforin and granzyme B [101], and secrete high levels of inflammatory cytokines such as interferon 
(IFN)-γ and TNF-α after short-term activation [102]. Besides the age-related thymus regression, the 
lifetime’s accumulated exposure to infectious agents, autoantigens, and cancer antigens may also 
induce T-cells replicative senescence and clonal exhaustion, a concept well-established in the case of 
chronic infections. 
Regarding innate immunity, it has been observed that neutr phils of aged populations show
decreased phagocytic activity against opsonized bacteria as well as a marked reduction in superoxide
generation [89]. Neutrophils play a key role in the defence against rapidly dividing bacteria, a major
cause of infection in the elder y [90,91]. Likewise, macroph ges also show diminished phagocytic
capability and superoxide productio , as well as diminishe l vels of MHC class II co plexes.
On the other hand, de dritic cells (DC) display decreased migrati n capability and alterations in
the phagocytic activity of apoptotic cells (reviewed in [89]).
Aging also has an important effect on adaptive immunity. Age-asso iated immunodeficie cy is
initially based on the involu ion of he thymus, the prim organ of T- ell development. Major chan s
observed in T-cell fun tions in old r adults are associated with the decrease i aïve T-cells and th
increase in ineffective memory T-cells [92,93]. Elderly populations possess lower levels of CD4(+) and
CD8(+) CD28(+) T-c lls ofte coupled with higher pro ortions of m mory CD8(+) T-cells [94]. Indeed,
one of the most important hallma ks of human immu e aging is the decrease in the bsolute number
and percentage of p ripheral blood naïve CD8(+) T-c lls [94]. A decrea e i vaccination efficacy in
older adults also correlates with g -ass ci te differences in the responses of CD4(+) and CD8(+)
T-cells to the vaccine, assoc ated in tur with variations i DC function [95].
In addition to the phenotype variations of the CD4(+) and CD8(+) T subpopulation, functional
changes of T-cells explain most of th age-rel ted path logies. Lymphocytes of elderly organi ms are
already in an activated stat , unable to b up-regulated by external stimu ation [96]. The most aff cted
T-cell functions ar clonal expansi n and cytokine production, pa ticularly IL-2 [97]. Addit onally,
a reduced proliferative activity of th se cells by s n scenc activation is observed. T-cells eng ge
the p38MAPK inhibitory signalling pathway in a apparently novel n -canonical mechanism [98].
So, by using small-molecule inhibitors [99] or specific inhibitory shRNA [100], it was observed that
p38MAPK inhibition r constituted proliferati n and telomerase activity in T-cells after activation.
Senescent T-cells also show high lev l of intracellu ar granules containing the cytotoxic proteins
perforin and granzyme B [101], and secrete high levels of inflammatory cytokines such as interferon
(IFN)-γ and TNF-α after short-term activation [102]. Besides the age-related thymus regression,
the lifetime’s accumulated exposure to infectious agents, autoantigens, and cancer antigens may also
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induce T-cells replicative senescence and clonal exhaustion, a concept well-established in the case of
chronic infections.
An increase in double negative (DN), IgD(−) CD27(−) B cells in elderly populations has been
observed that might be an exhausted pool of memory B cells [103]. These cells also have higher basal
levels of IL-10 and TNF-α production.
Autophagy dysfunction (macro-, micro-, and CM-autophagy), characteristic of aged
organisms [104], contributes to immunosenescence progression. Immune cells with autophagy
deficiency also display features of senescence, and in agreement with these data, T-cells and
macrophages show decreased autophagy when they are aged.
4. Senescence and Chronic Infections
4.1. Bacterial Infections and Senescence
Pseudomonas aeruginosa is an opportunistic pathogen able to cause infection in cornea and wounds,
as well as obstructive respiratory disease and cystic fibrosis [105,106]. Cystic fibrosis is a chronic,
asymptomatic disease related to a change in salt concentration due to a failure in the cystic fibrosis
transmembrane conductance regulator (CFTR) [107,108]. With the enlargement of the lifetime of
patients due to early specific treatment, the chronic infectious disease of the lung has emerged as
the main mortality cause in cystic fibrosis patients [109]. The pathogenesis of P. aeruginosa is due to
a battery of toxins that cause many effects.
One of the most important toxins is pyocyanin [110], which produces several effects such as
apoptosis induction [111], reduction in ciliary movement and sputum velocity in trachea [112,113],
change in the production of immune mediators [114,115], and abnormal characteristics and cytotoxicity
in skin explants [116] of infected people. Another important effect shown to be caused by pyocyanin is
the induction of oxidative stress in epithelial and endothelial cells [117,118]. The induction is moderate
but persistent, leading to a senescent phenotype [119]. In this case, the activation of senescence follows
the Erk/p38MAPK pathway [108]. Furthermore, pyocyanin is also able to activate the autophagic
pathway, which seems not to be related to oxidative stress [120]. Unfortunately, it is not possible
to correlate the effect of pyocyanin on autophagy with studies focused on senescence because the
experimental conditions are different [108,119,120]. A deeper study is necessary in order to know if
there is a relationship between the effect of pyocyanin on autophagy and senescence. Some strategies
are to monitoring autophagy and senescence in parallel on pyocyanin-treated cells by prolonged
time and use of drugs that modulate autophagy to see the effect of autophagy activation/inhibition
on senescence.
On the other hand, it has been recently observed that epithelial cells of CF patients present
an impaired autophagic response with overproduction of ROS and accumulation of aggresomes [121].
Indeed, an interesting study would be to analyse the effect of pyocyanin in normal cells or cells with
mutations in the CFTR regarding the senescence phenotype in the absence of an autophagic response.
In CF patients, the induction of senescence by P. aeruginosa in the airways might be particularly
important for chronic infection since senescence activation abrogates the normal desquamation process
of airway epithelia, thus allowing bacterial adhesion.
Indeed, bacteria take advantage in several ways of senescence activation. It has been proposed
that reactivation of Mycobacterium tuberculosis (Mtb) infection in aged individuals may be, in part,
due to senescence or immune exhaustion of T-cells. In aging, T cells expression levels of receptor
KLRG1, a receptor that inhibits T-cell function, is increased. Employing a KLRG1-KO mouse model,
increased bacterial survival has been demonstrated [122]. Interestingly, the authors proposed that
immunosenescence plays a role in the age-associated reactivation of tuberculosis and that KLRG1 is an
important participant in the process. Other observations indicate a rapid loss of Mtb-specific CD4+T
cells in HIV-infected subjects with active tuberculosis, which may be explained by the particularly
high susceptibility of these patients to the HIV-related immune damage and increased mortality [123].
Cells 2018, 7, 162 9 of 21
In addition, it has been also shown that co-infection of Mtb with HIV contributes to chronic immune
activation associated to senescence with functionally altered CD8+ T cells [124,125]. The co-infection
process results in an increased HIV viremia with a concomitant decrease in the CD4/CD8 T-cell
ratio, leading to suboptimal immune responses. The senescent CD8+ T-cells presented increased
levels of CD57 and CD38 with a concomitant decrease of co-stimulatory markers. Indeed, the levels
of intracellular IFN-γ, granzyme B, and perforin were diminished in CD8+ T-cells of HIV/Mtb
co-infected patients.
In the case of Mtb infection, it is clear that autophagy has a protective role for the cells against
the pathogen, representing an effective antimicrobial response. However, it has also been shown
that autophagy may exert inflammation modulation in the host to avoid adverse effects (reviewed
by Khan and Jagannath, 2017 [126]). On the other hand, cumulative evidence indicates that several
bacterial factors modulate certain components of the autophagic machinery to disrupt the proper
functioning of this pathway, but the impact of this disruption on immunosenescence activation
has not be addressed to date. One of the most studied Mycobacterium factors is the toxin ESAT-6.
Several functions have been described for this toxin, but particularly interesting is the inhibition of
the maturation of phagosomes/autophagosomes [30,127]. On the other hand, autophagy inducers,
such as rapamycin and IFN-γ, revert the inhibition in the maturation produced by Mycobacterium [128].
It is possible that blocking of autophagosomal maturation could predispose cells to activation of
senescence, and the use of positive modulators prevents the senescence activation. These data could
afford the development of new therapeutic strategies against tuberculosis.
Otherwise, a problem to take into account is the chronic and persistent antigenic stimulation,
such as bacterial chronic or latent infections that may cause T-cells’ late differentiation or exhaustion.
One typical example of this situation may be the chronic infection caused by Helicobacter pylori.
Curiously, in line with previous examples, H. pylori is able to activate senescence and to inhibit the
maturation of autophagosomes [129–131]. It has been described that CagA toxin activates senescence
by up-regulating p21 in an ERK-dependent manner [129]. VacA, another Helicobacter toxin, activates
autophagy [132] but by inhibition of the maturation of autophagosomes. Interestingly, besides the
effect on autophagy, VacA causes mitochondrial depolarization [133] and the disruption of autophagy
is accompanied by an elevation of ROS levels [134]. It would be interesting to study whether those
effects could collaborate in senescence activation.
Available evidence points to the autophagic pathway as a good candidate to be responsible for
senescence activation in chronic infection. This hypothesis is based on the fact that autophagic flux is
blocked in the majority of the examples mentioned above, a situation that predisposes infected cells to
damage accumulation. Indeed, further studies are necessary to corroborate this hypothesis.
4.2. The Chronic Trypanosoma Cruzi Infection
The intracellular protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease,
a chronic human infection endemic in Latin-American countries and currently extended to other
non-endemic places such as USA, Australia, and Spain. The infection is mainly transmitted by
contact with the faeces of an insect vector belonging to the Reduviidae family or by blood transfusion
and organs transplants. Parasites invade and replicate in different types of cells and expand the
infection by the blood until they reach their specific tissue targets [135]. Earlier in the invasion, T. cruzi
interacts with endocytic and autophagic pathways and the pre-induction of autophagy benefits the
infection by increasing host cell colonization [136]. However, the maturation of autophagosomes was
demonstrated to be impaired in infected cells [137]. The chronic disease, present in around 30% of the
infected population, is characterized by a persistent inflammatory reaction and destruction of host
cells, affecting mainly the peripheral autonomous nervous system of the gastrointestinal tract, the heart
muscle, and the cardiac nerves. Clinical symptoms are related to the development of megaesophagus,
megacolon, or cardiomegaly associated with progressive and untreatable heart failure [138]. Successful
persistence of parasites in muscle cells and neurons is due to the low efficacy of the currently available
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pharmacological treatments [139] and a dysfunctional immune response by the host. Similar to
autoimmune diseases, Chagas disease proceeds with lymphopenia and signs of T-cell senescence.
In T. cruzi-infected patients, T-cells CD8(+) and CD4(+) present markers of immunosenescence and
show an exhausted functional phenotype with diminished production of INF-gamma and IL-2 [140–
142]. The low frequency of INF-gamma producing CD8(+) T-cells and INF-gamma producing CD4(+)
T-cells specific for T. cruzi inversely correlates with disease severity [140–142]. On the other hand,
recent studies have also shown that the thymus is damaged during T. cruzi infection and, therefore,
lower numbers of conventional thymic T-cell emigrants and Tregs (regulatory T-lymphocytes) reach the
peripheral organs. Reduced T-cell renewal along the infection leads to an exacerbated adaptive immune
response similar to what has been previously described in other classical autoimmune diseases [143].
Therefore, immunosenescence and autoimmunity are key processes in the Chagas pathology that
prevail in about 30% of the infected population, allowing pathogen persistence and the generation of
the typical clinical symptoms of the disease.
Together with the evasion of the immune system, T. cruzi can also avoid autophagic intracellular
degradation through impairment of autophagosome maturation. Blockage of autophagy contributes,
like cellular stress protection, to senescence activation. One of the factors leading to parasite persistence
is the low efficacy of current treatments [139]. Exploring the roles of autophagy and senescence in
Chagas disease could open the door to new therapeutic strategies.
4.3. Persistent Human Cytomegalovirus Antigenic Stimulation and Immunosenescense: Possible Role for the
Autophagy Pathway
Paradigmatically, persistent viral infections represent the most evident cause of
immunosenescence. Contrary to acute infections, persistent infections have a more prolonged
duration, mainly because the immune system fails to clear the viral agent which usually resides
inside certain cell types (e.g., immune cells, neuronal cells, and epithelial cells). This kind of infection
alternates between both productive and silent infection without rapidly killing or even producing
excessive damage to the host cells. Varicella-zoster virus, measles virus, HIV-1, HHS-6, HHS-7, HSV-1,
HSV-2, and Human Cytomegalovirus (HCMV) are examples of viruses that cause typical persistent
infections and whose relation to human T-cell aging has been reviewed in Ref. [144].
Among the above-mentioned viral agents, HCMV merits a more detailed analysis since it causes
a unique effect on immunosenescence. HCMV is a viral pathogen belonging to the Herpesviridae
family. Clinically, the disease caused by HCMV infections is associated with immunocompromised
situations. In new-borns, HCMV infection is associated with deafness, mental retardation, and death,
while patients with AIDS often suffer retinitis, pneumonia, or gastrointestinal inflammation by the
presence of HCMV. In transplanted patients, the HCMV disease is associated with an increased rate
of graft rejection. Certainly, HCMV reactivates intermittently during the host’s lifetime, arguing
that sustained antigenic stimulation is the main cause of the virus-enhanced immunosenescence
detected in the elderly. However, studies conducted in young children infected with HCMV show
similar T-cell imbalance with an increase in memory CD8(+) T-cells and a decrease in the pool of
circulating naïve T-cells suggesting a mechanism of immunosenescence independently of the aging
process [145–147]. Thus, it is conceivable that such imbalance would be deleterious with a decreased
overall survival in the elderly associated with the viral infection, a hypothesis that has been confirmed
by epidemiological studies [148,149]. Additionally, anti-HCMV IgG titres in aged individuals have
been correlated with lower antibody responses to influenza virus [150–152]. However, other studies
observed the contrary [153,154], so, to date, the relationship between HCMV infections and accelerated
immunosenescence remains controversial. Recently, Redeker et al. hypothesized that the observed
discrepancies might be related to the variability in the infectious dose of HCMV occurring in real life
and they conducted a study to specifically address the role of the infectious dose on the contribution of
HCMV to accelerated immune senescence using a mouse model. They showed that the viral inoculum
size determines the degree of HCMV-induced immune alterations in lifelong infection. Furthermore,
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they demonstrated that infection alone caused by a high viral dose reduces newly generated CD8(+)
T-cell responses to heterologous super-infection [155].
Given that autophagy is involved in innate and adaptive immunity and it has been described as
an antiviral mechanism, it is not surprising that viruses encode proteins to counteract this process,
especially in herpesviruses, which are highly adapted to their hosts. HCMV belongs to the group
of herpesviruses which subverts autophagy for its own benefit. In this field, Dr. Esclatine´s group
and others have reported that HCMV stimulates autophagy early after fibroblasts infection and that
components of the viral particles, such as viral DNA, are sufficient to trigger this mechanism [156,157].
However, later on, the autophagic flux is blocked by the action of the viral proteins TRS1 and IRS1 [158].
Several viral proteins able to modulate autophagy act by interacting with BECN1, thus disrupting
autophagy, either at the autophagosome formation or at the maturation step [159]. The Nef protein
of HIV-1, [160], the M2 protein of influenza virus [161] and ICP34.5 of HSV-1 [162] suppress
autophagosome maturation into autolysosomes, likewise via their interaction with BECN1. Mouna and
collaborators [158] found that the coiled-coil domain (CCD) in BECN1, a universal oligomerization
domain, is the binding domain of IRS1. Notably, this CCD domain allows ATG14 and UVRAG (UV
radiation resistance associated) to interact with BECN1 in two distinct PtdIns3K-containing complexes
that function differentially in autophagosome formation and in the maturation of the endosome
and the autophagosome [163]. Their results suggest that individually, IRS1 and TRS1 may block
autophagosome biogenesis through the PtdIns3K-BECN1-ATG14 complex, and co-expression of these
two proteins may block the autophagy maturation process through the PtdIns3K BECN1-UVRAG
complex. Interestingly, the authors have shown that chemical induction of autophagy enhanced HCMV
production, while treatment with SPAUTIN (Specific and Potent Autophagy Inhibitor) produced
a decrease in viral titres. Therefore, it is likely that HCMV uses autophagic proteins or membranes
for its propagation. Indeed, understanding which steps of the herpes virus cycle are facilitated by
autophagy should be a major research focus for Herpes virologists.
To date, based on reported studies, HCMV-associated immunosenescence and HCMV–autophagy
interaction appear to be independent, but future prospective longitudinal studies will be required to
further delineate the contribution of HCMV-induced autophagy inhibition to immunosenescence and
to determine their impact in the process of aging. However, taken together, we hypothesize that the
autophagy-inhibited status of HCMV-infected cells might contribute to senescence of these cells in
addition to the immunosenescence induced by the persistence of circulating viral antigens.
5. Concluding Remarks
Senescence is induced as a consequence of cellular damage accumulation, with the extent of
activation directly depending on a fine-tuned balance between cellular conditions generating damage
and those involved in counteracting them. The autophagic pathway plays a key role in preventing
cell damage accumulation, however, the aging process leads to a decrease in autophagy capacity,
and therefore also its effectiveness. In this context, senescence activation shows a more preponderant
protective role.
The immune system does not escape from aging effects and displays senescence characteristics
in aged individuals. Immunosenescence refers to the state of dysregulated immune function
that contributes to the increased susceptibility to infections, autoimmune diseases, or cancer.
Aged individuals are predisposed to more severe symptoms from certain infections and they do not
mount an effective immune response upon vaccination. In general, aged populations fail to generate
an appropriate innate and adaptive immune response against microorganisms, thus it becomes clear
that senescence is involved in this failure.
Besides the normal occurrence of immunosenescence, several pathogen microorganisms accelerate
the activation of senescence and predisposal to premature immunosenescence (Figure 3). For instance,
hosts infected with bacteria such as P. aeuruginosa, M. tuberculosis, or H. pylori, some viruses, including
HCMV, or the parasite T. cruzi, show characteristics of immunosenescence (Table 2).
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Figure 3. One of the consequences of the aging process is the diminution of autophagic capacity.
Consequently, this diminution predisposes the individual to accumulation of cellular damage and
senescence activation. In the immune system, this process is called immunosenescence and is
accompanied by chronic inflammation. Several pathogens that induce chronic infections are able
to activate or accelerate the immunosenescence process and in this way, their elimination by the host
tends to be less effective.
Table 2. Effect of pathogens on autophagy and senescence.
Pathogen Autophagy Senescence
Pseudomonas aeruginosa Activated (pyocyanin) Activated (pyocyanin)
Mycobacterium tuberculosis Blocked autophagic flux (ESAT-6) Activated (immunosenescence)
Helicobacter pylori Blocked autophagic flux (VacA) Activated (CagA)
Trypanosoma cruzi ActivatedBlocked autophagic flux Activated
HCMV
Activated
Blocked autophagic flux
(TRS1 and IRS1)
Activated (immunosenescence)
A common issue of all of these pathogens is that they are able to generate chronic infections.
In each of these, regardless of the fact that the host is faced with the same antigen several times during
its lifetime, the immune r spo se is inefficient. Furthermore, data shows that this co dition generates
an immune exhaustion nd immunosenesc nce seems to be the major causative factor offering the
pathogens an extra advantage since their elimination by the host tends to be even less effective.
Nevertheless, there is also strong evidence that senescence activation does not necessarily depend
on a prolonged time of exposure of antigens to the immune system. HCMV is able to activate
senescence in children regardless of infection duration. Besides, there are some factors (toxins) that
can directly activate senescence, such as pyocyanin from P. aureginosa or CagA from H. pylori.
Interestingly, a common characteristic of chronic infections is the autophagy blockage that usually
occurs during autophagosome maturation, representing a factor that could contribute to or accelerate
immunosenescence activation since it predisposes cells to damage accumulation.
The majority of the examples here focus on the macroautophagy, which may be due to the
relationship between xenophagy and pathogens. Nevertheless, there are examples of CMA–pathogen
interactions. Salmonella enterica recruits Lamp2A and Hsp70 to its vacuole, favouring nutrient
acquisition by the bacteria [164], but the effect of this sequestration over cell homeostasis has not been
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studied yet. Unfortunately, we currently lack works focusing on the role of the autophagic pathway in
senescence activation when cells are infected with pathogens, or if the direct activation of senescence
by pathogens affects autophagy. Appropriate experiments must be conducted to specifically delineate
the role of autophagy (use of modulation drugs, knock out cells for Atg proteins, etc.) in senescence
regulation, and/or the opposite direction in infected models. One interesting question to solve is if
there is greater damage accumulation in cells when autophagy is blocked by pathogens, and if this
effect could produce or collaborate with other factors in the senescence response.
Then, deeper exploration to elucidate whether the activation of senescence in chronic infection
is a consequence of autophagy impairment produced by pathogens to avoid degradation or,
alternatively, whether it is a mechanism employed by the host to diminish infection spreading when
the degradation of the pathogens has been halted. This exploration is needed to further understand
the infection–autophagy–senescence relationship. With the available data, we hypothesize that chronic
infections induce senescence with similar characteristics of aging, i.e., increase of inflammatory state
and autophagy inhibition (Figure 3).
In some cases, pathogens have specific tools such as toxins that reinforce the effect of senescence
activation. This evidence denotes an important role of senescence in the survival of the pathogen.
The understanding of immune cells’ modifications in normal situations or in the context of chronic
infections should contribute to the design and development of novel therapeutic strategies to prevent
and treat such alterations.
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